LOS ANGELES, Feb. 22, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
three abstracts highlighting significant data relating to the
Company's LADR™ (Linker Activated Drug Release) drug candidates
have been selected for presentation at the 2018 Annual Meeting of
the American Association for Cancer Research (AACR) taking place
April 14-18, 2018 in Chicago.
"The discovery team at our expanded lab in Freiberg,
Germany have been busy generating
important data across several LADR™-derived ultra-high potency
compounds that we believe have breakthrough potential against
numerous solid tumors," said Steven A.
Kriegsman, CytRx's Chairman and CEO. "We are extremely
eager to advance these exciting programs and look forward to
sharing these new data with the medical and scientific community at
AACR this year."
Details for the poster presentations at AACR 2018:
Title: Structure-activity relationship studies and
biological evaluation of novel maytansinoids, a class of highly
selective tubulin inhibitors.
Abstract Number: 1657
Session Category and Title: Cancer Chemistry; Target
Based Drug Discovery
Session Date and Time: Monday, April 16, 2018;
8:00 a.m. to 12:00 p.m. CT
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 12
Title: Novel albumin-binding maytansinoids inducing
long-term partial and complete tumor regressions in several human
cancer xenograft models in nude mice.
Abstract Number: 2661
Session Category and Title: Cancer Chemistry; Antitumor
Agents
Session Date and Time: Monday Apr 16, 2018 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 1
Title: Superior efficacy of novel albumin-binding
auristatin E-based prodrugs compared to auristatin E in a panel of
human xenograft models in mice.
Abstract Number: 3703
Session Category and Title: Cancer Chemistry; Drug
Delivery
Session Date and Time: Tuesday Apr 17, 2018
8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster
Section 30
Poster Board Number: 3
About the LADR™ Technology Platform
CytRx's innovative LADR™ (Linker Activated Drug Release)
technology employs a broad portfolio of novel linker molecules that
selectively bind to circulating albumin and can be linked to a wide
variety of anti-cancer payloads. The Company's research
efforts currently center on creating new molecules from the
combination of ultra-high potency cytotoxic payloads with tunable
linkers. The molecules that CytRx is currently evaluating
concentrate at the tumor site providing targeted delivery of the
cell killing payloads.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a
biopharmaceutical company specializing in research and clinical
development of novel anti-cancer drug candidates that employ linker
technologies to enhance the accumulation and release of drug at the
tumor. CytRx is also rapidly expanding its pipeline of
ultra-high potency oncology candidates at its laboratory facilities
in Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker
technology for the development of a new class of potential
breakthrough anti-cancer
therapies. Aldoxorubicin, CytRx's most advanced drug
conjugate, is an improved version of the widely used anti-cancer
drug doxorubicin and has been out-licensed to NantCell,
Inc.
About AACR
The AACR is the oldest and largest scientific organization in
the world focused on every aspect of high-quality, innovative
cancer research. Its reputation for scientific breadth and
excellence attract the premier researchers in the field. The
programs and services of the AACR foster the exchange of knowledge
and new ideas among scientists dedicated to cancer research,
provide training opportunities for the next generation of cancer
researchers, and increase public understanding of cancer.
Presentations at the Annual Meeting will cover the latest basic,
translational, clinical, and prevention-focused research in the
field, including important areas such as early detection, cancer
interception, and survivorship in all populations.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including the ability
of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell,
Inc., to manufacture and commercialize products or therapies that
use aldoxorubicin; the amount, if any, of future milestone and
royalty payments that we may receive from NantCell, Inc.; our
ability to develop new ultra-high potency drug candidates based on
our LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date
of CytRx's most recent annual report. All forward-looking
statements are based upon information available
to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
michelle@argotpartners.com
sean@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-announces-the-presentation-of-new-ladr-candidate-data-at-the-american-association-for-cancer-research-2018-annual-meeting-300602591.html
SOURCE CytRx Corporation